Morana Vojnic1, Daisuke Kubota1, Christopher Kurzatkowski1, Michael Offin2, Ken Suzawa1, Ryma Benayed1, Adam J Schoenfeld2, Andrew J Plodkowski3, John T Poirier4, Charles M Rudin5, Mark G Kris5, Neal X Rosen6, Helena A Yu5, Gregory J Riely5, Maria E Arcila1, Romel Somwar7, Marc Ladanyi8. 1. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. 6. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: ladanyim@mskcc.org.
Abstract
INTRODUCTION: Multiple genetic mechanisms have been identified in EGFR-mutant lung cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs), but many cases still lack a known mechanism. METHODS: To identify novel mechanisms of AR, we performed targeted large panel sequencing of samples from 374 consecutive patients with metastatic EGFR-mutant lung cancer, including 174 post-TKI samples, of which 38 also had a matched pre-TKI sample. Alterations hypothesized to confer AR were introduced into drug-sensitive EGFR-mutant lung cancer cell lines (H1975, HCC827, and PC9) by using clustered regularly interspaced short palindromic repeats/Cas9 genome editing. MSK-LX138cl, a cell line with EGFR exon 19 deletion (ex19del) and praja ring finger ubiquitin ligase 2 gene (PJA2)/BRAF fusion, was generated from an EGFR TKI-resistant patient sample. RESULTS: We identified four patients (2.3%) with a BRAF fusion (three with acylglycerol kinase gene (AGK)/BRAF and one with PJA2/BRAF) in samples obtained at AR to EGFR TKI therapy (two posterlotinib samples and two posterlotinib and postosimertinib samples). Pre-TKI samples were available for two of four patients and both were negative for BRAF fusion. Induction of AGK/BRAF fusion in H1975 (L858R + T790M), PC9 (ex19del) and HCC827 (ex19del) cells increased phosphorylation of BRAF, MEK1/2, ERK1/2, and signal transducer and activator of transcription 3 and conferred resistance to growth inhibition by osimertinib. MEK inhibition with trametinib synergized with osimertinib to block growth. Alternately, a pan-RAF inhibitor as a single agent blocked growth of all cell lines with mutant EGFR and BRAF fusion. CONCLUSION: BRAF fusion is a mechanism of AR to EGFR TKI therapy in approximately 2% of patients. Combined inhibition of EGFR and MEK (with osimertinib and trametinib) or BRAF (with a pan-RAF inhibitor) are potential therapeutic strategies that should be explored.
INTRODUCTION: Multiple genetic mechanisms have been identified in EGFR-mutant lung cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs), but many cases still lack a known mechanism. METHODS: To identify novel mechanisms of AR, we performed targeted large panel sequencing of samples from 374 consecutive patients with metastatic EGFR-mutant lung cancer, including 174 post-TKI samples, of which 38 also had a matched pre-TKI sample. Alterations hypothesized to confer AR were introduced into drug-sensitive EGFR-mutant lung cancer cell lines (H1975, HCC827, and PC9) by using clustered regularly interspaced short palindromic repeats/Cas9 genome editing. MSK-LX138cl, a cell line with EGFR exon 19 deletion (ex19del) and praja ring finger ubiquitin ligase 2 gene (PJA2)/BRAF fusion, was generated from an EGFR TKI-resistant patient sample. RESULTS: We identified four patients (2.3%) with a BRAF fusion (three with acylglycerol kinase gene (AGK)/BRAF and one with PJA2/BRAF) in samples obtained at AR to EGFR TKI therapy (two posterlotinib samples and two posterlotinib and postosimertinib samples). Pre-TKI samples were available for two of four patients and both were negative for BRAF fusion. Induction of AGK/BRAF fusion in H1975 (L858R + T790M), PC9 (ex19del) and HCC827 (ex19del) cells increased phosphorylation of BRAF, MEK1/2, ERK1/2, and signal transducer and activator of transcription 3 and conferred resistance to growth inhibition by osimertinib. MEK inhibition with trametinib synergized with osimertinib to block growth. Alternately, a pan-RAF inhibitor as a single agent blocked growth of all cell lines with mutant EGFR and BRAF fusion. CONCLUSION:BRAF fusion is a mechanism of AR to EGFR TKI therapy in approximately 2% of patients. Combined inhibition of EGFR and MEK (with osimertinib and trametinib) or BRAF (with a pan-RAF inhibitor) are potential therapeutic strategies that should be explored.
Authors: Alexa B Schrock; Viola W Zhu; Wen-Son Hsieh; Russell Madison; Benjamin Creelan; Jeffrey Silberberg; Dan Costin; Anjali Bharne; Ioana Bonta; Thangavijayan Bosemani; Petros Nikolinakos; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Samuel J Klempner; Sai-Hong Ignatius Ou Journal: J Thorac Oncol Date: 2018-06-05 Impact factor: 15.609
Authors: Zongli Zheng; Matthew Liebers; Boryana Zhelyazkova; Yi Cao; Divya Panditi; Kerry D Lynch; Juxiang Chen; Hayley E Robinson; Hyo Sup Shim; Juliann Chmielecki; William Pao; Jeffrey A Engelman; A John Iafrate; Long Phi Le Journal: Nat Med Date: 2014-11-10 Impact factor: 53.440
Authors: Lee Spraggon; Luciano G Martelotto; Julija Hmeljak; Tyler D Hitchman; Jiang Wang; Lu Wang; Emily K Slotkin; Pang-Dian Fan; Jorge S Reis-Filho; Marc Ladanyi Journal: J Pathol Date: 2017-03-30 Impact factor: 7.996
Authors: H S Kim; M Jung; H N Kang; H Kim; C-W Park; S-M Kim; S J Shin; S H Kim; S G Kim; E K Kim; M R Yun; Z Zheng; K Y Chung; J Greenbowe; S M Ali; T-M Kim; B C Cho Journal: Oncogene Date: 2017-01-16 Impact factor: 9.867
Authors: Sheng-Bin Peng; James R Henry; Michael D Kaufman; Wei-Ping Lu; Bryan D Smith; Subha Vogeti; Thomas J Rutkoski; Scott Wise; Lawrence Chun; Youyan Zhang; Robert D Van Horn; Tinggui Yin; Xiaoyi Zhang; Vipin Yadav; Shih-Hsun Chen; Xueqian Gong; Xiwen Ma; Yue Webster; Sean Buchanan; Igor Mochalkin; Lysiane Huber; Lisa Kays; Gregory P Donoho; Jennie Walgren; Denis McCann; Phenil Patel; Ilaria Conti; Gregory D Plowman; James J Starling; Daniel L Flynn Journal: Cancer Cell Date: 2015-09-03 Impact factor: 31.743
Authors: Zofia Piotrowska; Hideko Isozaki; Jochen K Lennerz; Justin F Gainor; Inga T Lennes; Viola W Zhu; Nicolas Marcoux; Mandeep K Banwait; Subba R Digumarthy; Wenjia Su; Satoshi Yoda; Amanda K Riley; Varuna Nangia; Jessica J Lin; Rebecca J Nagy; Richard B Lanman; Dora Dias-Santagata; Mari Mino-Kenudson; A John Iafrate; Rebecca S Heist; Alice T Shaw; Erica K Evans; Corinne Clifford; Sai-Hong I Ou; Beni Wolf; Aaron N Hata; Lecia V Sequist Journal: Cancer Discov Date: 2018-09-26 Impact factor: 39.397
Authors: Ryma Benayed; Michael Offin; Kerry Mullaney; Purvil Sukhadia; Kelly Rios; Patrice Desmeules; Ryan Ptashkin; Helen Won; Jason Chang; Darragh Halpenny; Alison M Schram; Charles M Rudin; David M Hyman; Maria E Arcila; Michael F Berger; Ahmet Zehir; Mark G Kris; Alexander Drilon; Marc Ladanyi Journal: Clin Cancer Res Date: 2019-04-26 Impact factor: 12.531
Authors: Hiroki Sato; Adam J Schoenfeld; Evan Siau; Yue Christine Lu; Huichun Tai; Ken Suzawa; Daisuke Kubota; Allan J W Lui; Besnik Qeriqi; Marissa Mattar; Michael Offin; Masakiyo Sakaguchi; Shinichi Toyooka; Alexander Drilon; Neal X Rosen; Mark G Kris; David Solit; Elisa De Stanchina; Monika A Davare; Gregory J Riely; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2020-03-02 Impact factor: 12.531
Authors: Adam J Schoenfeld; Joseph M Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C Chang; Paul K Paik; Michael Offin; Maria E Arcila; Monika A Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G Kris; Romel Somwar; Gregory J Riely; Marc Ladanyi; Helena A Yu Journal: Clin Cancer Res Date: 2020-01-07 Impact factor: 12.531
Authors: Igor Odintsov; Allan J W Lui; Whitney J Sisso; Eric Gladstone; Zebing Liu; Lukas Delasos; Renate I Kurth; Exequiel M Sisso; Morana Vojnic; Inna Khodos; Marissa S Mattar; Elisa de Stanchina; Shawn M Leland; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2021-04-06 Impact factor: 12.531
Authors: Jia Luo; Alex Makhnin; Yosef Tobi; Linda Ahn; Sara A Hayes; Afsheen Iqbal; Kenneth Ng; Maria E Arcila; Gregory J Riely; Mark G Kris; Helena A Yu Journal: JCO Precis Oncol Date: 2021-01-11